TSE:EXE Extendicare (EXE) Stock Price, News & Analysis C$14.34 -0.08 (-0.55%) As of 05/30/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesBuy This Stock About Extendicare Stock (TSE:EXE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Extendicare alerts:Sign Up Key Stats Today's RangeC$14.25▼C$14.4550-Day RangeC$12.65▼C$14.7352-Week RangeC$7.10▼C$15.24Volume306,964 shsAverage Volume189,131 shsMarket CapitalizationC$1.20 billionP/E Ratio18.28Dividend Yield3.35%Price TargetC$13.50Consensus RatingHold Company OverviewExtendicare Inc., operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.Read More… Extendicare Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreEXE MarketRank™: Extendicare scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingExtendicare has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageExtendicare has only been the subject of 1 research reports in the past 90 days.Read more about Extendicare's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Extendicare is 18.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Extendicare is 18.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.05.Price to Book Value per Share RatioExtendicare has a P/B Ratio of 10.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for EXE. Dividend2.5 / 5Dividend StrengthModerate Dividend LeadershipExtendicare is a leading dividend payer. It pays a dividend yield of 4.42%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthExtendicare does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Extendicare is 61.20%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Extendicare's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for EXE. News and Social Media2.4 / 5News Sentiment0.40 News SentimentExtendicare has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Extendicare this week, compared to 1 article on an average week.Search InterestOnly 12 people have searched for EXE on MarketBeat in the last 30 days. This is a decrease of -37% compared to the previous 30 days.MarketBeat Follows1 people have added Extendicare to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Extendicare insiders have not sold or bought any company stock.Percentage Held by Insiders13.92% of the stock of Extendicare is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.16% of the stock of Extendicare is held by institutions.Read more about Extendicare's insider trading history. Receive EXE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Extendicare and its competitors with MarketBeat's FREE daily newsletter. Email Address EXE Stock News HeadlinesThis TSX Monthly Dividend Stock Down 25% Pays an Incredible Dividend YieldMay 31 at 2:43 PM | ca.finance.yahoo.comThis 3.5% Dividend Stock Pays Cash Every Single MonthMay 30 at 6:40 PM | msn.comTrump Knows Exactly What He's DoingREVEALED: $194 Trillion Trump Market Pattern Trump fires off a tweet and stocks tank… He gives a speech and the markets soar… Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets. And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance.June 1, 2025 | Brownstone Research (Ad)Extendicare Inc: Extendicare Announces Voting Results for its 2025 Annual and Special Meeting of ShareholdersMay 28, 2025 | finanznachrichten.deExtendicare (TSE:EXE) Price Target Raised to C$15.00May 25, 2025 | americanbankingnews.comEarnings call transcript: Extendicare’s Q1 2025 earnings beat estimates, stock dropsMay 9, 2025 | uk.investing.comExtendicare Inc. declares CAD 0.042 dividendMay 6, 2025 | msn.com5 Canadian Monthly Dividend Stocks to Buy and Hold in Your TFSA for Retirement IncomeApril 28, 2025 | msn.comSee More Headlines EXE Stock Analysis - Frequently Asked Questions How have EXE shares performed this year? Extendicare's stock was trading at C$10.63 at the beginning of the year. Since then, EXE shares have increased by 34.9% and is now trading at C$14.34. View the best growth stocks for 2025 here. How were Extendicare's earnings last quarter? Extendicare Inc. (TSE:EXE) announced its quarterly earnings data on Tuesday, November, 12th. The company reported $0.19 EPS for the quarter. Extendicare had a net margin of 4.48% and a trailing twelve-month return on equity of 64.13%. Read the conference call transcript. How do I buy shares of Extendicare? Shares of EXE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Extendicare own? Based on aggregate information from My MarketBeat watchlists, some other companies that Extendicare investors own include Enbridge (ENB), Enterprise Products Partners (EPD), Algonquin Power & Utilities (AQN), Bank of Nova Scotia (BNS), NVIDIA (NVDA), Pembina Pipeline (PPL) and BCE (BCE). Company Calendar Last Earnings11/12/2024Ex-Dividend for 5/15 Dividend4/30/2025Record date for 5/15 Dividend5/15/2025Dividend Payable5/15/2025Ex-Dividend for 6/16 Dividend5/30/2025Today5/31/2025Record date for 6/16 Dividend6/16/2025Dividend Payable6/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Medical Care Facilities Sub-IndustryN/A Current SymbolTSE:EXE CIKN/A Webwww.extendicare.com Phone905-470-4000FaxN/AEmployees23,000Year FoundedN/APrice Target and Rating Average Stock Price TargetC$13.50 High Stock Price TargetC$15.00 Low Stock Price TargetC$11.00 Potential Upside/Downside-5.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C$0.78 Trailing P/E Ratio18.28 Forward P/E Ratio23.38 P/E GrowthN/ANet IncomeC$65.46 million Net Margins4.48% Pretax MarginN/A Return on Equity64.13% Return on Assets7.16% Debt Debt-to-Equity Ratio283.02 Current Ratio0.62 Quick Ratio0.98 Sales & Book Value Annual SalesC$1.46 billion Price / Sales0.82 Cash FlowC$4.48 per share Price / Cash Flow3.20 Book ValueC$1.40 per share Price / Book10.28Miscellaneous Outstanding Shares83,467,000Free FloatN/AMarket CapC$1.20 billion OptionableNot Optionable Beta1.26 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (TSE:EXE) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Extendicare Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Extendicare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.